Industry News

Cipla Limited on Tuesday announced its unaudited consolidated financial results for the second quarter of FY2026–27, reporting operating revenue of ₹7,404 crore, down 2% year-on-year from ₹7,589 crore in the corresponding quarter last year.

Dr. Reddys Laboratories Ltd announced that the Central Drugs Standard Control Organisation (CDSCO), under the Drugs Controller General of India (DCGI), has approved Zytorvi® (toripalimab) in combination with cisplatin and paclitaxel for the first-line treatment of adult patients with unresectable advanced, recurrent or metastatic esophageal squamous cell carcinoma (ESCC).

Eli Lilly and Company has announced new analyses of clinical trial data showing that its drug Omvoh (mirikizumab-mrkz) helped some patients with moderately to severely active ulcerative colitis and Crohn’s disease achieve multiple treatment goals simultaneously at one year.

Biocon Limited has entered into a global patent settlement and licence agreement with Genentech, a member of the Roche Group, resolving pending disputes over Pebrilzo® (bPertuzumab), its biosimilar version of Perjeta® (pertuzumab), a biologic medicine used in the treatment of HER2-positive breast cancer.

Zydus Lifesciences Limited and Formycon AG have announced that the US Food and Drug Administration (USFDA) has accepted the Biologics License Application (BLA) for FYB206, a proposed biosimilar to Keytruda® (pembrolizumab), for review.

Viatris Inc. has agreed to acquire Pacira BioSciences Inc. in an all-cash transaction valued at approximately 1.65 billion USD, marking a significant step in its strategy to expand its innovative medicines business.

Pfizer has announced that the US Food and Drug Administration (FDA) has approved TUKYSA (tucatinib) in combination with trastuzumab and pertuzumab for the maintenance treatment of adults with unresectable locally advanced or metastatic HER2-positive breast cancer following induction treatment.

Bristol Myers Squibb (BMS) has announced positive results from its Phase III EXCALIBER-RRMM study, demonstrating superior progression-free survival with ZENBEXUS (iberdomide) in combination with daratumumab and dexamethasone in patients with relapsed or refractory multiple myeloma.